• Improving In Vitro Evaluation of Antineoplastic Drug Respons

  2026-07-14

  Schwartz's dissertation introduces improved in vitro methods to distinguish proliferative arrest from cell death in cancer drug testing, emphasizing the need for precise viability metrics. The work provides actionable insights for optimizing drug-response assays, influencing how researchers assess agents like dacarbazine in preclinical models.

• STING agonist-1: Precision Workflows for B Cell Activation R

  2026-07-14

  STING agonist-1 enables immunology and oncology labs to dissect B cell-mediated antitumor immunity and tertiary lymphoid structure dynamics with reproducible precision. This guide delivers actionable workflows, troubleshooting insights, and practical translation of recent mechanistic findings for advanced cancer immunotherapy research.

• Mechanisms of ZAK Activation at Collided Ribosomes in Stress

  2026-07-13

  This study uncovers the structural and mechanistic principles by which the MAP3K ZAK is activated on ribosomes during translational stress. The findings clarify how ribosome collisions, mediated by RACK1, organize ZAK activation and highlight regulatory inputs that prevent inappropriate stress signaling, providing a blueprint for dissecting kinase-driven cellular responses.

• Dantrolene Sodium Salt: Precision RyR Antagonist in CRISPR W

  2026-07-13

  Dantrolene sodium salt, a potent ryanodine receptor antagonist, empowers researchers to modulate intracellular calcium release and DNA repair pathway outcomes with nanomolar precision. This article delivers actionable experimental guidance, troubleshooting strategies, and protocol enhancements for CRISPR and disease modeling applications where calcium signaling control is pivotal.

• Bleomycin Sulfate in Pulmonary Fibrosis and DNA Damage Model

  2026-07-12

  Bleomycin Sulfate (Blenoxane) is the gold standard for modeling pulmonary fibrosis and chemotherapy-induced DNA damage, supporting both mechanistic and translational studies. This guide details protocols, troubleshooting, and the latest workflow advances, empowering researchers to generate reproducible, pathway-targeted outcomes with confidence.

• Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Model

  2026-07-10

  Quizartinib (AC220) delivers unmatched selectivity and potency for dissecting FLT3-driven signaling and resistance in acute myeloid leukemia (AML) research. This guide translates the latest mechanistic insights and reference breakthroughs into actionable protocols, troubleshooting strategies, and advanced applications for in vitro and in vivo studies.

• Quizartinib (AC220): Precision FLT3 Inhibition for AML Resea

  2026-07-09

  Quizartinib (AC220) empowers acute myeloid leukemia (AML) researchers to dissect FLT3-driven signaling and resistance using highly selective, nanomolar-range inhibition. This guide delivers actionable workflows, troubleshooting strategies, and next-level protocol insights to leverage Quizartinib's unique strengths in both in vitro and in vivo models.

• Aprotinin (BPTI) in Translational Research: Mechanisms, Impa

  2026-07-09

  This thought-leadership article explores the mechanistic underpinnings and translational strategies surrounding Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI), with a focus on its role in serine protease inhibition, perioperative blood loss reduction, and inflammation modulation. Bridging evidence from cardiovascular surgery research and advanced transcriptomic workflows, it offers protocol guidance and competitive insights for translational researchers poised to exploit Aprotinin’s unique biochemical properties in complex experimental systems.

• BCECF in Microenvironmental pH Regulation: Principles to Pre

  2026-07-08

  Explore how BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) enables advanced, quantitative analysis of extracellular pH microenvironments in biomedical research. This in-depth guide reveals unique methodological insights and practical assay strategies distinct from existing resources.

• Bleomycin Sulfate: Protocols and Pitfalls for Pulmonary Fibr

  2026-07-08

  Bleomycin Sulfate is a DNA strand break inducer widely used to model chemotherapy-induced DNA damage and pulmonary fibrosis, especially for mechanistic studies involving TGF-β/Smad and JAK-STAT signaling pathways. This article details protocol parameters, solubility considerations, and workflow best practices to optimize reproducibility in both in vitro and in vivo settings. Avoid use where precise long-term solution stability or ethanol solubility is required.

• Bromodomain Inhibitor (+)-JQ1: Multi-Pathway Modulation & Pr

  2026-07-07

  Explore the multi-dimensional impact of Bromodomain Inhibitor, (+)-JQ1 on chromatin regulation, apoptosis, and cytokine storm modulation. This article uniquely integrates mechanistic insights, protocol parameters, and assay guidance for advanced BET bromodomain inhibitor research.

• Amitriptyline HCl in High-Throughput BBB & Neuropharmacology

  2026-07-07

  Amitriptyline HCl empowers rigorous in vitro blood-brain barrier (BBB) and receptor modulation assays, enabling nuanced CNS drug discovery workflows. This workflow-focused review highlights key innovations, protocol optimizations, and troubleshooting strategies to maximize translational impact with this APExBIO tricyclic research compound.

• Dasatinib (BMS-354825): Optimizing Kinase Assays in Cancer M

  2026-07-06

  Dasatinib (BMS-354825) unlocks precise, multi-kinase targeting for advanced oncology workflows, enabling researchers to dissect Src and Bcr-Abl signaling in both cellular and animal systems. Leveraging recent breakthroughs in EMT and stemness mechanisms, this guide translates cutting-edge insights into robust experimental protocols and troubleshooting strategies.

• Macrophage-Derived EV miR-660 Drives Breast Cancer Metastasi

  2026-07-06

  This study uncovers how tumor-associated macrophage (TAM)-derived extracellular vesicles (EVs) transfer microRNA-660 to breast cancer cells, promoting metastasis via suppression of KLHL21 and activation of the IKKβ/NF-κB p65 pathway. The findings highlight a critical non-cell-autonomous mechanism in breast cancer progression and suggest new avenues for targeting TAM-EV-miRNA interactions.

• Sex Differences in Cannabinoid Withdrawal Revealed by WIN 55

  2026-07-05

  Brewer et al. systematically investigated somatic and anxiety-like withdrawal behaviors in male and female rats following exposure to the synthetic cannabinoid agonist WIN 55,212-2. Their findings uncover distinct sex-specific behavioral signatures during withdrawal, with implications for endocannabinoid system modulator research and preclinical modeling of cannabinoid dependence.

14685 records 1/979 page Next 12345 下5页 Last page